CDKN3 and neoplasm: In conclusion, by stratifying the patients based on age, gender, MYCN amplification status and tumor stage, results from the three datasets clearly supported the correlation of high CDKN3 level with poor patient survival probability in all age and gender groups, in MYCN-nonamplified group and in stages 2 - 4 groups.